Toshiki Hatanaka
Toshiki Hatanaka has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Akiyoshi Ohtake
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
3 shared publicationsAkiyoshi Someya
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
3 shared publicationsKoji Ueshima
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
3 shared publicationsMai Watanabe
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
3 shared publicationsMasanori Suzuki
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
3 shared publicationsMasashi Ukai
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
3 shared publications
Latest Publications
- 6 July 2013
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (11) , 1001-1008
Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys
Mirabegron is a novel β3-adrenoceptor agonist developed for the treatment of overactive bladder. To clarify the relationship between the pharmacological effects of mirabegron in monkeys and the clinical efficacy in patients with overactive bladder, the effect of mirabegron on bladder function was evaluated using cynomolgus monkeys. Quantitative PCR revealed that mRNA expression of β3-adrenoceptors was most abundant (98 %) among β-adrenoceptor subtypes in the bladder of cynomolgus monkeys. Mirabegron, which showed selective and potent agonistic activity on monkey β3-adrenoceptors expressed in Chinese hamster ovary cells with EC50 value of 32 nmol/L and intrinsic activity of 0.8, induced concentration-dependent relaxation of bladder smooth muscle strips isolated from cynomolgus monkeys with EC50 values of 120 nmol/L in 20 mmol/L KCl stimulation and 43 nmol/L under 9.81 mN resting tension. In conscious cynomolgus monkeys, mirabegron decreased micturition frequency at oral doses of 1 and 3 mg/kg and increased mean volume voided per micturition at an oral dose of 3 mg/kg. Plasma concentration at which bladder function improved in the cynomolgus monkeys was similar to that at the clinically effective dose in patients with overactive bladder. These data suggest that the relaxant function in monkey bladder is mainly mediated by β3-adrenoceptors similar to that in the human bladder and mirabegron showed efficacy on the bladder functions of the same parameters in clinical evaluation endpoints.
- 6 July 2013
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (11) , 1001-1008
Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys
Mirabegron is a novel β3-adrenoceptor agonist developed for the treatment of overactive bladder. To clarify the relationship between the pharmacological effects of mirabegron in monkeys and the clinical efficacy in patients with overactive bladder, the effect of mirabegron on bladder function was evaluated using cynomolgus monkeys. Quantitative PCR revealed that mRNA expression of β3-adrenoceptors was most abundant (98 %) among β-adrenoceptor subtypes in the bladder of cynomolgus monkeys. Mirabegron, which showed selective and potent agonistic activity on monkey β3-adrenoceptors expressed in Chinese hamster ovary cells with EC50 value of 32 nmol/L and intrinsic activity of 0.8, induced concentration-dependent relaxation of bladder smooth muscle strips isolated from cynomolgus monkeys with EC50 values of 120 nmol/L in 20 mmol/L KCl stimulation and 43 nmol/L under 9.81 mN resting tension. In conscious cynomolgus monkeys, mirabegron decreased micturition frequency at oral doses of 1 and 3 mg/kg and increased mean volume voided per micturition at an oral dose of 3 mg/kg. Plasma concentration at which bladder function improved in the cynomolgus monkeys was similar to that at the clinically effective dose in patients with overactive bladder. These data suggest that the relaxant function in monkey bladder is mainly mediated by β3-adrenoceptors similar to that in the human bladder and mirabegron showed efficacy on the bladder functions of the same parameters in clinical evaluation endpoints.
- 14 December 2012
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (3) , 247-253
In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats
To investigate the pharmacological properties of mirabegron in in vitro and in vivo, the effects on cAMP accumulation in Chinese hamster ovary (CHO) cells expressing rat β-adrenoceptors, the relaxant activity in isolated rat bladder smooth muscle, and the voiding effects in cerebral infarcted rats were evaluated. Mirabegron increased cAMP accumulation with EC50 value and intrinsic activity of 19 nmol/L and 1.0, respectively, in CHO cells expressing rat β3-adrenoceptors. The EC50 values and the intrinsic activities of mirabegron were 610 nmol/L and 0.6 for rat β1-adrenoceptors and were sumless and 0.1 for β2-adrenoceptors, respectively. Mirabegron showed concentration-dependent relaxant and full agonistic effects in rat bladder strips under passive tension with EC50 value of 290 nmol/L. The concentration–response curve of mirabegron was affected neither by the β1-adrenoceptor selective antagonist CGP-20712A nor by the β2-adrenoceptor selective antagonist ICI-118,551. In in vivo studies with cerebral infarcted rats, a significant decrease in the volume voided per micturition compared with sham-operated rats was observed. Mirabegron dose-dependently increased the volume voided per micturition. In conclusion, we have extended the selectivity profile of mirabegron to rats and demonstrated that it is effective via stimulation of β3-adrenoceptors in a rat cerebral infarction model of detrusor overactivity.
- 14 December 2012
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (3) , 247-253
In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats
To investigate the pharmacological properties of mirabegron in in vitro and in vivo, the effects on cAMP accumulation in Chinese hamster ovary (CHO) cells expressing rat β-adrenoceptors, the relaxant activity in isolated rat bladder smooth muscle, and the voiding effects in cerebral infarcted rats were evaluated. Mirabegron increased cAMP accumulation with EC50 value and intrinsic activity of 19 nmol/L and 1.0, respectively, in CHO cells expressing rat β3-adrenoceptors. The EC50 values and the intrinsic activities of mirabegron were 610 nmol/L and 0.6 for rat β1-adrenoceptors and were sumless and 0.1 for β2-adrenoceptors, respectively. Mirabegron showed concentration-dependent relaxant and full agonistic effects in rat bladder strips under passive tension with EC50 value of 290 nmol/L. The concentration–response curve of mirabegron was affected neither by the β1-adrenoceptor selective antagonist CGP-20712A nor by the β2-adrenoceptor selective antagonist ICI-118,551. In in vivo studies with cerebral infarcted rats, a significant decrease in the volume voided per micturition compared with sham-operated rats was observed. Mirabegron dose-dependently increased the volume voided per micturition. In conclusion, we have extended the selectivity profile of mirabegron to rats and demonstrated that it is effective via stimulation of β3-adrenoceptors in a rat cerebral infarction model of detrusor overactivity.
- 9 December 2012
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (1) , 71-78
Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats
- 9 December 2012
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (1) , 71-78
Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats